SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
- Disease/Condition
- Hepatitis C, Chronic
- Drug/Device/Intervention
- SH229 tablets
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Location
- Jilin, China
- Phase
- Phase 2/3
- Start date
- Mar 29, 2019
- End date
- Aug 01, 2020
- Enrollment
- 440 participants
Sustained virologic response at 12 weeks after end of treatment (SVR12)
Phase II: Exploring the efficacy and safety of different doses of SH229 tablets combined with
 fixed-dose Daclatasvi dihydrochloride (DCV) tablets in the treatment of adult patients with
 chronic hepatitis C for 12 weeks, providing a basis for the design and implementation of
 phase III clinical trials.
 
 Phase III: Confirmation of the efficacy and safety of SH229 tablets combined with Daclatasvi
 dihydrochloride (DCV) tablets in the treatment of adult patients with chronic hepatitis C for
 12 weeks, providing a sufficient basis for drug registration and clinical use.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT04070235
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT04070235 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Nanjing Sanhome Pharmaceutical, Co., Ltd. and is currently status unknown. The study focuses on Hepatitis C, Chronic. Target enrollment is 440 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.